Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.
Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.
复制标题
DOI：
10.1111/j.2040-1124.2011.00109.x
复制
发表时间：
2011-10-07
影响因子：
3.2
通讯作者：
Seino Y
中科院分区：
文献类型：
--
作者：
Kubota A;Matsuba I;Saito T;Nabe K;Seino Y
我们对40例接受西格列汀治疗的日本2型糖尿病患者进行了回顾性分析。 糖化血红蛋白（HbA1c）和空腹血糖分别从基线时的7.53 ± 0.65%和155.2 ± 29.4 mg/dL显著降低至第20周时的6.80 ± 0.60%（P <0.01）和131.2 ± 22.3 mg/dL（P <0.01）。 通过移植胰岛分泌单位（SUIT）指数评价β细胞功能，SUIT指数从基线时的28.5 ± 14.0显著增加至20周时的38.6 ± 17.0（P <0.01）。 将Δ HbA1c与多个参数（年龄、糖尿病病程、体重指数、甘油三酯[TG]、C肽[CPR]、Δ CPR、HbA1c [基线]和Δ SUIT）进行多因素分析，结果显示HbA1c（基线; β = 0.580，P <0.001）和Δ SUIT（β = 0.308，P <0.05）是Δ HbA1c的显著独立决定因素。 这两个变量解释了HbA1c反应的53%方差。这些结果表明，SUIT指数可以作为西格列汀治疗糖尿病疗效的临床指标。（J Diabetes Invest，doi：10.1111/j.2040 - 1124.2011.00109.x，2011）
We carried out a retrospective analysis of 40 Japanese patients with type 2 diabetes mellitus who received sitagliptin. Glycated hemoglobin (HbA1c) and fasting plasma glucose were significantly decreased from 7.53 ± 0.65% and 155.2 ± 29.4 mg/dL at baseline to 6.80 ± 0.60% (P < 0.01) and 131.2 ± 22.3 mg/dL (P < 0.01) at week 20, respectively. β‐Cell function was evaluated by the secretory units of islets in transplantation (SUIT) index, which was significantly increased from 28.5 ± 14.0 at baseline to 38.6 ± 17.0 at week 20 (P < 0.01). Multivariate analysis was carried out between ΔHbA1c and several parameters (age, the duration of diabetes, body mass index, triglyceride [TG], C‐peptide [CPR], ΔCPR, HbA1c [baseline] and ΔSUIT), which showed HbA1c (baseline; β = 0.580, P < 0.001) and ΔSUIT (β = 0.308, P < 0.05) as significant independent determinants of ΔHbA1c. These two variables explained 53% of the variance in HbA1c response. These results suggest that SUIT index can be a clinical marker for the efficacy of sitagliptin in treatment of diabetes mellitus. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00109.x, 2011)
登录
查看更多内容
影响因子：
2
作者：
Iwamoto, Yasuhiko;Taniguchi, Tadaaki;Amatruda, John
通讯作者：
Amatruda, John
影响因子：
6.7
作者：
Herman, G. A.;Stein, P. P.;Wagner, J. A.
通讯作者：
Wagner, J. A.
影响因子：
4.2
作者：
Ahren, Bo
通讯作者：
Ahren, Bo
影响因子：
5.8
作者：
Iwamoto, Y.;Tajima, N.;Amatruda, J. M.
通讯作者：
Amatruda, J. M.
影响因子：
5.8
作者：
Hermansen, K.;Kipnes, M.;Stein, P.
通讯作者：
Stein, P.